OptimizeRx Co. (NASDAQ:OPRX) Stake Increased by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its stake in OptimizeRx Co. (NASDAQ:OPRX) by 189.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,690 shares of the company’s stock after acquiring an additional 2,414 shares during the period. BNP Paribas Financial Markets’ holdings in OptimizeRx were worth $28,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. First Light Asset Management LLC raised its stake in shares of OptimizeRx by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock valued at $18,270,000 after purchasing an additional 89,377 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in OptimizeRx by 24.0% in the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after buying an additional 119,306 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in OptimizeRx by 12.5% during the second quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock valued at $3,241,000 after buying an additional 35,957 shares in the last quarter. Essex Investment Management Co. LLC lifted its holdings in OptimizeRx by 42.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock worth $1,868,000 after buying an additional 72,672 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of OptimizeRx by 101.8% in the 2nd quarter. Renaissance Technologies LLC now owns 142,146 shares of the company’s stock worth $1,421,000 after acquiring an additional 71,700 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Stephens initiated coverage on OptimizeRx in a research report on Friday. They set an “equal weight” rating and a $5.50 price target on the stock. Roth Mkm reissued a “buy” rating and set a $16.00 target price (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Royal Bank of Canada reduced their price target on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Barclays lowered their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. Finally, William Blair reissued an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.71.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. This trade represents a 3.44 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.10% of the stock is owned by company insiders.

OptimizeRx Stock Up 3.4 %

OPRX stock opened at $4.91 on Friday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm’s 50-day simple moving average is $5.41 and its 200 day simple moving average is $7.87. The stock has a market cap of $90.45 million, a PE ratio of -3.69 and a beta of 1.34. OptimizeRx Co. has a fifty-two week low of $3.78 and a fifty-two week high of $16.65.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.